Cargando…

Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab

Panitumumab is a fully humanized monoclonal antibody with a high degree of affinity for the extracellular domain of the epidermal growth factor receptor. Phase II clinical evaluation of this drug, when administered as a single agent, in patients with metastatic colorectal cancer refractory to chemot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoda, Daanish, Simon, George R, Garrett, Christopher R
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2008
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2643103/ https://www.ncbi.nlm.nih.gov/pubmed/19337429

Ejemplares similares

Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab
por: Williams, Kerry J, et al.
Publicado: (2009)

Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab
por: Kim, George P, et al.
Publicado: (2008)

Clinical Pharmacokinetics and Pharmacodynamics of the Epidermal Growth Factor Receptor Inhibitor Panitumumab in the Treatment of Colorectal Cancer
por: Ketzer, Sander, et al.
Publicado: (2017)

Leukocytoclastic vasculitis with purpura and renal failure induced by the anti-epidermal growth factor receptor antibody panitumumab: a case report
por: Kamo, Hitomi, et al.
Publicado: (2019)

Treatment of metastatic colorectal cancer: focus on panitumumab
por: Tay, Rebecca Y, et al.
Publicado: (2015)

Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer
por: Braig, Friederike, et al.
Publicado: (2015)

Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy
por: Price, Timothy, et al.
Publicado: (2020)

Panitumumab Plus Trifluridine-Tipiracil as Anti–Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial
por: Napolitano, Stefania, et al.
Publicado: (2023)

Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer
por: Freeman, Daniel J, et al.
Publicado: (2012)

REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer
por: Nakajima, Hiromichi, et al.
Publicado: (2021)

Long-Term Treatment of Metastatic Colorectal Cancer with Panitumumab
por: López-Gómez, Miriam, et al.
Publicado: (2012)

Patient considerations in metastatic colorectal cancer – role of panitumumab
por: Rogers, Jane E
Publicado: (2017)

Management of skin toxicities during panitumumab treatment in metastatic colorectal cancer
por: Bouché, Olivier, et al.
Publicado: (2019)

Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer
por: Berardi, Rossana, et al.
Publicado: (2010)

Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status
por: Peeters, Marc, et al.
Publicado: (2015)

Effectiveness and safety of capecitabine, irinotecan and panitumumab in advanced colorectal cancer
por: Yip, Pui Lam, et al.
Publicado: (2023)

Association between serum ligands and the skin toxicity of anti-epidermal growth factor receptor antibody in metastatic colorectal cancer
por: Takahashi, Naoki, et al.
Publicado: (2015)

Panitumumab: the evidence of its therapeutic potential in metastatic colorectal cancer care
por: Martinelli, Erika, et al.
Publicado: (2007)

Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer
por: Carvalho, Adriana Camargo, et al.
Publicado: (2017)

Cicatricial ectropion and madarosis associated with panitumumab treatment of metastatic colorectal cancer
por: Jin, Haoxing D., et al.
Publicado: (2020)

Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors
por: García-Foncillas, Jesús, et al.
Publicado: (2019)

Targeting Epidermal Growth Factor Receptor (EGFR) in Pediatric Colorectal Cancer
por: De Pasquale, Maria Debora, et al.
Publicado: (2020)

Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies
por: Diaz Miqueli, A, et al.
Publicado: (2009)

Optimizing Single Agent Panitumumab Therapy in Pre-Treated Advanced Colorectal Cancer()()
por: Gasparini, Giampietro, et al.
Publicado: (2014)

Biologic Response of Colorectal Cancer Xenograft Tumors to Sequential Treatment with Panitumumab and Bevacizumab
por: Taniguchi, Hiroya, et al.
Publicado: (2018)

Panitumumab-Induced Eruptive Seborrhoeic Keratosis in a Patient with Metastatic Colorectal Cancer
por: Koumaki, Dimitra, et al.
Publicado: (2020)

Panitumumab-Associated Drug-Induced Immune Thrombocytopenia in a Patient with Colorectal Cancer
por: Takamizawa, Shigemasa, et al.
Publicado: (2021)

EGFR monoclonal antibody panitumumab inhibits chronic proliferative cholangitis by downregulating EGFR
por: Liu, San-Hu, et al.
Publicado: (2019)

Review on comparative efficacy of bevacizumab, panitumumab and cetuximab antibody therapy with combination of FOLFOX-4 in KRAS-mutated colorectal cancer patients
por: Pathak, Surajit, et al.
Publicado: (2017)

A novel therapeutic strategy of personalized medicine based on anti-epidermal growth factor receptor monoclonal antibodies in patients with metastatic colorectal cancer
por: Matsuhashi, Nobuhisa, et al.
Publicado: (2018)

Oncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancer
por: Sobani, Zain A, et al.
Publicado: (2016)

Epidermal Growth Factor Receptor Mutations in Colorectal Cancer Patients
por: Oh, Bo-Young, et al.
Publicado: (2011)

Near infrared photoimmunotherapy targeting bladder cancer with a canine anti-epidermal growth factor receptor (EGFR) antibody
por: Nagaya, Tadanobu, et al.
Publicado: (2018)

Targeted α-Particle Radiation Therapy of HER1-Positive Disseminated Intraperitoneal Disease: An Investigation of the Human Anti-EGFR Monoclonal Antibody, Panitumumab
por: Milenic, Diane E., et al.
Publicado: (2017)

Hepatocellular carcinoma treated with anti-epidermal growth factor receptor antibody nimotuzumab: A case report
por: Song, Peng, et al.
Publicado: (2017)

Interleukin-4 receptor and epidermal growth factor receptor expression in colorectal cancer.
por: Kaklamanis, L., et al.
Publicado: (1992)

Targeting the epidermal growth factor receptor
por: El-Rayes, B F, et al.
Publicado: (2004)

Epidermal Growth Factor Receptor as Target for Perioperative Elimination of Circulating Colorectal Cancer Cells
por: Gruijs, Mandy, et al.
Publicado: (2022)

Development of Irinotecan Liposome Armed with Dual-Target Anti-Epidermal Growth Factor Receptor and Anti-Fibroblast Activation Protein-Specific Antibody for Pancreatic Cancer Treatment
por: Lin, Hung-Jun, et al.
Publicado: (2022)

Priming of Colorectal Tumor-Associated Fibroblasts with Zoledronic Acid Conjugated to the Anti-Epidermal Growth Factor Receptor Antibody Cetuximab Elicits Anti-Tumor Vδ2 T Lymphocytes
por: Fernandez, Jordi Leonardo Castrillo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_95mhia00uob725lloqiio1f9ku